Research and Markets: Stakeholder Insight: Lung Cancer - Third-Generation Cytotoxics Set to Dominate the Market.Business Editors/Health/Medical Writers DUBLIN, Ireland--(BUSINESS WIRE)--April 22, 2004 Third-Generation Cytotoxics, Such as Gemcitabine, Vinorelbine and Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , Are Increasingly Being Prescribed to SCLC SCLC abbr. Southern Christian Leadership Conference Patients as Nearly 423,000 New Cases of SCLC and NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there Were Diagnosed in the Seven Major Pharmaceutical Markets in 2003 Research and Markets (http://www.researchandmarkets.com) has announced the addition of Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. Insight: Lung Cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. - Third-Generation Cytotoxics Set to Dominate the Market to their offering. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. our estimate, nearly 423,000 new cases of SCLC and NSCLC are expected to be diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs in the disease in terms of poor survival. This report examines the current diagnosis and treatment trends of lung cancer in the seven major markets. Scope Analysis of Lung cancer treatment based on a survey of 152 clinical oncologists and pulmonologists in the 7 major markets Diagnosis patterns of SCLC and NSCLC, including stage distribution and physician types responsible for diagnosis Report Highlights Third-generation cytotoxics, such as gemcitabine, vinorelbine and paclitaxel, are increasingly being prescribed to SCLC patients. Having reached an efficacy plateau with cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic. cis·plat·in n. and etoposide regimen, we believe that physicians will increasingly experiment with third-generation chemotherapy that have proven to be effective in NSCLC. Reasons to Purchase Assess the number of drug-treated population of lung cancer in the seven major markets Enhance your commercial positioning by understanding the dynamics of current lung cancer drugs Scope Percentage use of various treatment modalities treatment modality Medtalk The method used to treat a Pt for a particular condition for SCLC and NSCLC by stage Report Highlights Cisplatin plus Campto (irinotecan) is the gold-standard regimen for extensive SCLC in Japan, based on the results of a Japanese trial. Physicians in the US and Europe are generally skeptical of the regimen and it will not see a wide uptake until the results are replicated in a Western clinical trial. Aventis' Taxotere (docetaxel) has the potential to become the gold-standard first-line therapy for NSCLC in the US. However, we believe that this is unlikely to be the case in the European markets, where Lilly's Gemzar (gemcitabine) and Pierre Fabre/GSK's Navelbine (vinorelbine) will continue to dominate the NSCLC market. Region: Japan, US, Europe Report Contents: Richard Faint - Director of Oncology Chapter 1 EXECUTIVE SUMMARY Chapter 2 INTRODUCTION AND SCOPE Chapter 3 COUNTRY TREATMENT TREES Chapter 4 DEFINITION AND EPIDEMIOLOGY Chapter 5 DIAGNOSIS AND REFERRAL Chapter 6 TREATMENT POPULATION Chapter 7 TREATMENT MODALITIES FOR SCLC Chapter 8 TREATMENT MODALITIES FOR NSCLC Chapter 9 FIRST-LINE DRUG REGIMENS Chapter 10 SECOND-LINE DRUG second-line drug Any therapeutic agent that is not the drug of choice, or the 1st normally used to treat a particular condition; in rheumatoid arthritis, 2nd REGIMENS Chapter 11 PRESCRIBING FACTORS & DRUG PROFILES Chapter 12 TREATMENT OUTCOMES Chapter 13 FUTURE Chapter 14 POPULATION DATA APPENDIX A BIBLIOGRAPHY LIST OF TABLES LIST OF FIGURES APPENDIX C For more information visit http://www.researchandmarkets.com/reports/c1427 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion